Erratum: A novel cell-based screen identifies chemical entities that reverse the immune-escape phenotype of metastatic tumours

Frontiers Production Office,

doi:10.3389/fphar.2023.1233717

ERRATUM article

Front. Pharmacol. , 12 June 2023

Sec. Pharmacology of Anti-Cancer Drugs

Volume 14 - 2023 | https://doi.org/10.3389/fphar.2023.1233717

Erratum: A novel cell-based screen identifies chemical entities that reverse the immune-escape phenotype of metastatic tumours

This article is an erratum on:

A novel cell-based screen identifies chemical entities that reverse the immune-escape phenotype of metastatic tumours
1. Read original article

Frontiers Production Office*

Frontiers Media SA, Lausanne, Switzerland

An Erratum on
A novel cell-based screen identifies chemical entities that reverse the immune-escape phenotype of metastatic tumours

by Nohara LL, Ellis SLS, Dreier C, Dada S, Saranchova I, Munro L, Pfeifer CG, Coyle KM, Morrice JR, Shim DJS, Ahn P, De Voogd N, Williams DE, Cheng P, Garrovillas E, Andersen RJ and Jefferies WA (2023). Front. Pharmacol. 14:1119607. doi: 10.3389/fphar.2023.1119607

Due to a production error, “Eliana Al Haddad” and “Kyong Bok Choi” were not included as authors in the published article. The corrected Author contributions and Acknowledgments statements appear below.

Author contributions

Conceived Project: WJ; Designed research: LN, SE, CP, DW, RA, and WJ; Performed research: LN, SE, SD, IS, LM, KC, CD, JM, DS, PA, BE, ND, DW, PC, and EG; Analyzed data: LN, SE, SD, IS, LM, CP, KC, CD, JM, DS, PA, BE, TM, ND, DW, PC, NL, EG, RA, and WJ; Wrote the paper: LN, SE, RA, and WJ; Edited the paper: LN, SE, CP, TM, DW, NL, EG, RA, and WJ.

Acknowledgments

We would like to thank Professor Michel Roberge for critical discussion and access to the Cellomics Screening System.

The publisher apologizes for these mistakes. The original version of this article has been updated.

Keywords: antigen processing machinery, curcuphenol, major histocompatibility complex class I, metastatic tumours, natural products, high throughput cell-based assay, drug discovery

Citation: Frontiers Production Office (2023) Erratum: A novel cell-based screen identifies chemical entities that reverse the immune-escape phenotype of metastatic tumours. Front. Pharmacol. 14:1233717. doi: 10.3389/fphar.2023.1233717

Received: 02 June 2023; Accepted: 02 June 2023;
Published: 12 June 2023.

Approved by:

Frontiers Editorial Office, Frontiers Media SA, Switzerland

Copyright © 2023 Frontiers Production Office. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

*Correspondence: Frontiers Production Office, cHJvZHVjdGlvbi5vZmZpY2VAZnJvbnRpZXJzaW4ub3Jn

Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.

Erratum: A novel cell-based screen identifies chemical entities that reverse the immune-escape phenotype of metastatic tumours

Author contributions

Acknowledgments

95% of researchers rate our articles as excellent or good

95% of researchers rate our articles as excellent or good